Method for Treating Osteoporosis
AssigneeExelixis, Inc.
InventorsDana T. Aftab, Douglas Clary
Life of this patent
Estimating the term…
Abstract
This invention is directed to the treatment of osteoporosis using N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
Claims15
A method for treating osteoporosis, comprising administering to a patient in need of such treatment a compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is halo;
- R2 is halo;
- R3 is (C1-C6)alkyl;
- R4 is (C1-C6)alkyl;
- and
- Q is CH or N.
A method for treating osteoporosis in patients who have or are currently undergoing treatment for cancer, comprising administering a pharmaceutical composition comprising Compound of Formula I or the malate salt of Compound of Formula I or another pharmaceutically acceptable salt of Compound of Formula I.
A method for ameliorating abnormal deposition of unstructured bone accompanied by increased skeletal fractures, spinal cord compression, and severe bone pain of osteoporosis, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula I in any of the embodiments disclosed herein.
A prognostic method for osteoporosis in a subject, comprising:
- (a) measuring the level of P1NP, CTx or TRACP 5b in a sample form the subject;
- (b) comparing the level of P1NP, CTx or TRACP 5b measured in step (a) to a standard level of P1NP, CTx or TRACP 5b to determine if the sample from the subject has aberrant levels of P1NP, CTx or TRACP 5b;
- (c) selecting a treatment regimen with the Compound of Formula I, Ia, or 1 based on aberrant levels of P1NP, CTx or TRACP 5b or administering the Compound of Formula I, Ia, or 1 according to the treatment regimen such that the osteoporosis is inhibited in the subject.
A method for stimulating osteoblast differentiation and/or activity in a patient in need of such treatment, comprising administering to the patient an effect amount of a Compound of Formula I, Ia, or Compound 1.
A method for stimulating bone formation in a patient in need of such treatment, comprising administering to the patient an effect amount of a Compound of Formula I, Ia, or Compound 1.
A method for inhibiting osteoclast differentiation and/or activity in a patient in need of such treatment, comprising administering to the patient an effect amount of a Compound of Formula I, Ia, or Compound 1
A method for modulating bone turnover toward bone formation in a patient in need of such treatment, comprising administering to the patient an effect amount of a Compound of Formula I, Ia, or Compound 1.
Dependencies are inferred from the claim text.